newsfilter
← Latest News
ACCESS Newswire·

Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Company Highlights Significant Regulatory, Clinical and Strategic Progress Across SkinJect® and Teverelix® Programs and a Strengthened Financial Position Supporting Continued Pipeline Execution and Expansion